[1] Zhang N, Wei C, Du H, Shi FD, Cheng Y. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-tomoderate Alzheimer's disease patients[J]. Dement Geriatr Cogn Disord, 2015, 40:85-93. [2] Costanza A, Xekardaki A, Kövari E, Gold G, Bouras C, Giannakopoulos P. Microvascular burden and Alzheimer-type lesions across the age spectrum[J]. J Alzheimers Dis, 2012, 32:643-652. [3] Berlow YA, Wells WM, Ellison JM, Sung YH, Renshaw PF, Harper DG. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease[J]. Int J Geriatr Psychiatry, 2010, 25:780-788. [4] Steingart A, Hachinski VC, Lau C, Fox AJ, Fox H, Lee D, Inzitari D, Merskey H. Cognitive and neurologic findings in demented patients with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis)[J]. Arch Neurol, 1987, 44:36-39. [5] Lampe L, Kharabian-Masouleh S, Kynast J, Arelin K, Steele CJ, Löffler M, Witte AV, Schroeter ML, Villringer A, Bazin PL. Lesion location matters:the relationships between white matter hyperintensities on cognition in the healthy elderly[J]. J Cereb Blood Flow Metab, 2019, 39:36-43. [6] Mak E, Dwyer MG, Ramasamy DP, Au WL, Tan LC, Zivadinov R, Kandiah N. White matter hyperintensities and mild cognitive impairment in Parkinson's disease[J]. J Neuroimaging, 2015, 25:754-760. [7] Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7:257-262. [8] Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease[J]. Ann Neurol, 1997, 42:85-94. [9] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state":a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12:189-198. [10] Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment:validity and utility in a memory clinic setting[J]. Can J Psychiatry, 2007, 52:329-332. [11] Eto F, Tanaka M, Chishima M, Igarashi M, Mizoguchi T, Wada H, Iijima S. Comprehensive activities of daily living (ADL) index for the elderly[J]. Nihon Ronen Igakkai Zasshi, 1992, 29:841-848. [12] Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale[J]. J Psychiatri Res, 2000, 34:3-10. [13] Wang T, Xiao S, Li X, Wang H, Liu Y, Su N, Fang Y. Reliability and validity of the Chinese version of the neuropsychiatric inventory in mainland China[J]. Int J Geriatr Psychiatry, 2012, 27:539-544. [14] Morris JC. The Clinical Dementia Rating (CDR):current version and scoring rules[J]. Neurology, 1993, 43:2412-2414. [15] Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging[J]. AJR Am J Roentgenol, 1987, 149:351-356. [16] Wang SS, Zhang Z, Zhu TB, Chu SF, He WB, Chen NH. Myelin injury in the central nervous system and Alzheimer's disease[J]. Brain Res Bull, 2018, 140:162-168. [17] Mortamais M, Artero S, Ritchie K. White matter hyperintensities as early and independent predictors of Alzheimer's disease risk[J]. J Alzheimers Dis, 2014, 42 Suppl 4:393-400. [18] Bos D, Wolters FJ, Darweesh SKL, Vernooij MW, de Wolf F, Ikram MA, Hofman A. Cerebral small vessel disease and the risk of dementia:a systematic review and meta-analysis of population-based evidence[J]. Alzheimers Dement, 2018, 14:1482-1492. [19] Zonneveld HI, Goos JD, Wattjes MP, Prins ND, Scheltens P, van der Flier WM, Kuijer JP, Muller M, Barkhol F. Prevalence of cortical superficial siderosis in a memory clinic population[J]. Neurology, 2014, 82:698-704. [20] Sarabia-Cobo CM, Pérez V, Hermosilla C, Nuñez MJ, de Lorena P. Apathy and leukoaraiosis in mild cognitive impairment and Alzheimer's disease:multicenter diagnostic criteria according to the latest studies[J]. Dement Geriatr Cogn Dis Extra, 2014, 4: 228-235. [21] Han F, Zhai FF, Wang Q, Zhou LX, Ni J, Yao M, Li ML, Zhang SY, Cui LY, Jin ZY, Zhu YC. Prevalence and risk factors of cerebral small vessel disease in a Chinese population-based sample[J]. J Stroke, 2018, 20:239-246. [22] Naganuma T, Takemoto Y, Shoji T, Shima H, Ishimura E, Okamura M, Nakatani T. Factors associated with cerebral white matter hyperintensities in haemodialysis patients[J]. Nephrology (Carlton), 2012, 17:561-568. [23] Sierra C, Coca A. White matter lesions and cognitive impairment as silent cerebral disease in hypertension[J]. Scientific World J, 2006, 6:494-501. [24] Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease[J]. Arch Neurol, 2002, 59:787-793. [25] Moran C, Phan TG, Srikanth VK. Cerebral small vessel disease:a review of clinical, radiological, and histopathological phenotypes[J]. Int J Stroke, 2012, 7:36-46. [26] de Leeuw FE, de Groot JC, van Gijn J. Cerebral white matter lesions in the elderly:vascular risk factors and cognitive consequences[J]. Ned Tijdschr Geneeskd, 2001, 145:2067-2071. [27] Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer's disease:a focus on myelin and oligodendrocytes[J]. Acta Neuropathol Commun, 2018, 6:22. [28] Lee MJ, Seo SW, Na DL, Kim C, Park JH, Kim GH, Kim CH, Noh Y, Cho H, Kim HJ, Yoon CW, Ye BS, Chin J, Jeon S, Lee JM, Choe YS, Lee KH, Kim JS, Kim ST, Lee JH, Ewers M, Werring DJ, Weiner MW. Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment[J]. JAMA Psychiatry, 2014, 71:412-422. [29] Kynast J, Lampe L, Luck T, Frisch S, Arelin K. White matter hyperintensities associated with small vessel disease impair social cognition beside attention and memory[J]. J Cereb Blood Flow Metab, 2018, 38:996-1009 [30] van den Berg E, Geerlings MI, Biessels GJ, Nederkoorn PJ, Kloppenborg RP. White matter hyperintensities and cognition in mild cognitive impairment and Alzheimer's disease:a domain-specific meta-analysis[J]. J Alzheimers Dis, 2018, 63:515-527. [31] van der Flier WM, van Straaten EC, Barkhof F, Verdelho A, Madureira S, Pantoni L, Inzitari D, Erkinjuntti T, Crisby M, Waldemar G, Schmidt R, Fazekas F, Scheltens P. Small vessel disease and general cognitive function in nondisabled elderly:the LADIS study[J]. Stroke, 2005, 36:2116-2120. [32] Tiehuis AM, Vincken KL, Mali WP, Kappelle LJ, Anbeek P, Algra A, Biessels GJ. Automated and visual scoring methods of cerebral white matter hyperintensities:relation with age and cognitive function[J]. Cerebrovasc Dis, 2008, 25:59-66. [33] Soriano-Raya JJ, Miralbell J, López-Cancio E, Bargalló N, Arenillas JF, Barrios M, Cáceres C, Toran P, Alzamora M, Dávalos A, Mataró M. Deep versus periventricular white matter lesions and cognitive function in a community sample of middle-aged participants[J]. J Int Neuropsychol Soc, 2012, 18:874-885. [34] Kao YH, Chou MC, Chen CH, Yang YH. White matter changes in patients with Alzheimer's disease and associated factors[J]. J Clin Med, 2019, 8:167. [35] van Agtmaal MJM, Houben AJHM, Pouwer F, Stehouwer CDA, Schram MT. Association of microvascular dysfunction with late-life depression:a systematic review and meta-analysis[J]. JAMA Psychiatry, 2017, 74:729-739. [36] Hollocks MJ, Lawrence AJ, Brookes RL, Barrick TR, Morris RG, Husain M, Markus HS. Differential relationships between apathy and depression with white matter microstructural changes and functional outcomes[J]. Brain, 2015, 138(Pt 12):3803-3815. [37] Fischer CE, Qian W, Schweizer TA, Millikin CP, Ismail Z, Smith EE, Lix LM, Shelton P, Munoz DG. Lewy bodies, vascular risk factors, and subcortical arteriosclerotic leukoencephalopathy, but not Alzheimer pathology, are associated with development of psychosis in Alzheimer's disease[J]. J Alzheimers Dis, 2016, 50:283-295. [38] Palmqvist S, Sarwari A, Wattmo C, Bronge L, Zhang Y, Wahlund LO, Nägga K. Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer's disease[J]. Dement Geriatr Cogn Disord, 2011, 32:417-423. [39] Anor CJ, O'Connor S, Saund A, Tang-Wai DF, Keren R, Tartaglia MC. Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia[J]. Neurodegener Dis, 2017, 17:127-134. [40] Tully PJ, Debette S, Mazoyer B, Tzourio C. White matter lesions are associated with specific depressive symptom trajectories among incident depression and dementia populations:three-city Dijon MRI study[J]. Am J Geriatr Psychiatry, 2017, 25:1311-1321. [41] Hahn C, Lim HK, Won WY, Ahn KJ, Jung WS, Lee CU. Apathy and white matter integrity in Alzheimer's disease:a whole brain analysis with tract-based spatial statistics[J]. PLoS One, 2013, 8:e53493. [42] Jonsson M, Edman A, Lind K, Rolstad S, Sjögren M, Wallin A. Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia[J]. Int J Geriatr Psychiatry, 2010, 25:588-595. [43] Kim J, Schweizer TA, Fischer CE, Munoz DG. The role of cerebrovascular disease on cognitive and functional status and psychosis in severe Alzheimer's disease[J]. J Alzheimers Dis, 2017, 55:381-389. [44] Lee DY, Choo IH, Kim KW, Jhoo JH, Youn JC, Lee UY, Woo JI. White matter changes associated with psychotic symptoms in Alzheimer's disease patients[J]. J Neuropsychiatry Clin Neurosci, 2006, 18:191-198. |